miRNAs in the Era of Personalized Medicine: From Biomarkers to Therapeutics

Bárbara Andrea Mc Cormack, Eva González-Cantó, Cristina Agababyan, Agababyan C, Nancy Adriana Espinoza‐Sánchez, Nancy A Espinoza-Sánchez, Tomás-Pérez S, Sarai Tomás-Pérez, Llueca A, Josep Marí‐Alexandre, Martin Götte, Juan Gilabert–Estellés, Juan Gilabert-Estellés
International journal of molecular sciences · 2021 · vol. 22(15) · doi:10.3390/ijms22158154 · PMID:34360918 · PMC8348078
Review OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-20 ⓘ

This review discusses the role of microRNAs in personalized medicine, highlighting their potential applications as biomarkers and therapeutic agents for various diseases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-20 · read from full text ⓘ

This review article explores the evolving role of microRNAs in personalized medicine, detailing their potential utility as biomarkers for disease diagnosis and prognosis. The authors examine current methodologies for detecting miRNA expression profiles and discuss emerging strategies for developing miRNA-based therapeutics across various pathological contexts. A primary limitation noted is the technical complexity and standardization challenges associated with translating these molecular findings into routine clinical practice. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In recent years, interest in personalized medicine has considerably increased [...].
Full text 881 characters · extracted from epmc-fulltextxml · 4 sections · click to expand

Author

Conceptualization, B.A.M.C., and J.M.-A.; Methodology (literature review and selection of manuscripts): B.A.M.C., E.G.-C., C.A., S.T.-P. and A.L.; writing—original draft preparation, B.A.M.C. and E.G.-C.; writing—review and editing, N.A.E.-S., J.M.-A., M.G. and J.G.-E.; supervision, J.M.-A., M.G. and J.G.-E. Funding acquisition, J.G.-E. and J.M.-A. All authors have read and agreed to the published version of the manuscript.

Funding

This work has been supported by grants from ISCIII-FEDER “Una manera de hacer Europa” (PI17/01945), from Generalitat Valenciana (GV/2020/200, APOSTD/2019/087 and ACIF/2020/216) and from General University Hospital of Valencia (Prize FIHGUV 2019 and Prize FIHGUV 2020).

Fn Group

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Conflicts

The authors declare that no conflict of interest exists.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

MicroRNAs Neoplasms Precision Medicine Biomarkers Biomarkers Humans MicroRNAs Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:32:03.440833+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC